Orexigen Therapeutics has secured Takeda Pharmaceutical as a partner for its obesity drug Contrave® (naltrexone SR/bupropion SR), which is awaiting marketing approval in the US. The value of the deal may exceed US$1 B, although the modest US$50 M upfront payment reflects the risk profile of obesity drugs.